Expert oncologist discuss key data from 2023 on the detection and treatment of prostate cancer.
EP. 1: Evolving Paradigms in the Detection and Treatment of Prostate Cancer
Expert oncologists offer insights into conquering resistance, reimagining screening, and realizing the paradigm-shifting potential of advances in biomarker-driven precision medicine.
EP. 2: Evolving Insights into Castration Resistance: Novel Biomarkers Predicting Disease Progression
Dr. Tanya Dorff and Dr. Rana McKay discuss the mechanisms driving castration resistance and how emerging epigenetic biomarkers may transform prognosis.
EP. 3: Data from the DEAR Real-World Study and Strategies for Optimizing Outcomes
Drs. Dorff and McKay discuss real-world data from DEAR trial comparing darolutamide, enzalutamide and apalutamide, providing clinical pearls on their experiences to optimize outcomes.
EP. 4: Revolutionizing Prostate Cancer Care: 2023’s Transformative Breakthroughs
Expert oncologists highlight 2023’s transformative new targeted therapies and phase 3 data sets transforming the treatment paradigm in advanced prostate cancer.
Time to Bladder Cancer Treatment Is Similar Among Black and White Patients, But Other Disparities Persist
Dr Jia on the Evolving Role of Metastasis-Directed Radiotherapy in Prostate Cancer
Dr Wang on the Limited Utility of Quantitative Molecular Imaging Thresholds in RCC
Darolutamide Use Is Routine in Both Doublets and Triplet Therapies in mHSPC